gene-modified T cells targeted for Leukemia
This study is evaluating whether modified T cells can be safely given to patients with ALL.
See full descriptionAbout the trial for Leukemia
Treatment Groups
This trial involves 2 different treatments. Gene-modified T Cells Targeted is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.
Eligibility
This trial is for patients born any sex aged 18 and older. You must have received 1 prior treatment for Leukemia or one of the other 3 conditions listed above. There are 10 eligibility criteria to participate in this trial as listed below.
Approximate Timelines
Measurement Requirements
This trial is evaluating whether gene-modified T cells targeted will improve 1 primary outcome and 1 secondary outcome in patients with Leukemia. Measurement will happen over the course of 2 years.
Patient Q & A Section
What are the signs of leukemia?
While some of the signs of leukemia are similar to those of multiple sclerosis, there are more specific signs of leukemia. Patients with leukemia may have an increased risk of developing multiple sclerosis. There are also signs to look for when considering whether a patient has leukemia.
Can leukemia be cured?
There is an urgent need for new and better therapies for leukemias. Clinical and translational researches will be important to further evaluate the role of HDACi administration in leukemia therapy.
What causes leukemia?
Causes of leukemias include genetic and environmental carcinogens, viral infections and hematopoietic stem cell defects. Leukemias may arise from mutations in genes for cytokines or cell surface receptors. Radiation therapy and chemotherapy may also play a role in acute leukemia and chronic leukemia, respectively.\n
What is leukemia?
There are 3 types of blood cancers: myeloid leukemia, lymphoid leukemia, and acute leukemia/b-cell lymphoma. Leukemia can have a debilitating effect on patients and occasionally lead to very early deaths. Lymphoma is a group of cancers, including various subtypes of B-, T- and NK- cell lymphomas. The most common form is Non-Hodgkin's lymphoma, as it is also the most common type of leukemia in the United States.
What are common treatments for leukemia?
Patients with leukemia receive various therapies. There is no cure, but the goals of treatment are to stop cancer growth and reduce the risk of recurrent cancer growth.
How many people get leukemia a year in the United States?
A high prevalence of acute and chronic lymphoid leukemia is observed, making the incidence of both extremely low. The incidence of CLL is lower and the incidence of AML is higher than in Europe and in the Japanese population. In AML, the number of people diagnosed with this disease decreases from the southern part of the country to the northern part, in accordance with a high incidence of AML on the north-eastern part of the U.S. It is possible that lifestyle changes and the ageing of the population may be linked with low CLL incidence in the northern portion of the country.
Does gene-modified t cells targeted improve quality of life for those with leukemia?
Immune cell therapy is an effective treatment for patients with metastatic leukemia. Gene-modified T cells redirected to leukemia cells will improve quality of life, and increase the chance to survive cancer.
Have there been other clinical trials involving gene-modified t cells targeted?
The use of CD19-targeted gene-modified T cells can represent an important avenue of further evaluation of gene-modified T cells targeting B cells. Results from a recent clinical trial has been helpful for the future design and application of these cells as therapeutic agents. Nevertheless, the CD19-targeted T-cell therapy and the immune functions of T cells remain major aspects of treatment for allogeneic stem cell transplantation (allo-SCT). It would be critical to determine, in the future, if CD19-targeted gene-modified T cells provide significant benefits in combating the malignancies for which allograft transplantation has been used for many years.
How does gene-modified t cells targeted work?
Results from a recent clinical trial establishes that CAR-T cells targeting CD19 are a promising therapy in vitro. It is hoped that a gene therapy approach will improve both the safety and efficacy that can be realized in human clinical applications.
What is the latest research for leukemia?
A lot happens every week and it is hard to keep up with the latest research. I am so busy with a lot of other studies that I could not find information about leukemia for this article. So please ask your doctor. If the latest research is important, take it to your doctor.
What is the survival rate for leukemia?
Survival rate for newly diagnosed patients with AML has declined in New England/New Jersey from 1974-2005 whereas survival was similar in the rest of the country. More than 70% of patients with newly diagnosed AML were eligible for allogeneic or autologous bone marrow transplantation. In this cohort, a 1-year event-free survival of >45% existed and in spite of higher rates of relapse or progression in more recent years. This suggests a shift in treatment from induction chemotherapy with anthracycline, and then transplantation to high-dose regimen therapy with autologous and allogeneic transplantation for newly diagnosed patients with AML.
Is gene-modified t cells targeted safe for people?
Gene-modified T cells represent an exciting treatment tool for cancer that is available for use in humans. There are many barriers to their use including risk, cost, and the need for repeated injections. The clinical significance of the use of gene-modified T cells is a contentious issue. Data from a recent study from this phase I study suggest that these cell types may be safe and can be safely administered peripherally when combined with a common, well tolerated chemotherapy.